Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970-2015

JAMA - Journal of the American Medical Association

Volumn 317, Issue 8, 2017, Pages 814-824

  Turcotte, Lucie M ^a   Liu, Qi ^b   Yasui, Yutaka ^b,c   Arnold, Michael A ^d   Hammond, Sue ^d   Howell, Rebecca M ^e   Smith, Susan A ^e   Weathers, Rita E ^e   Henderson, Tara O ^f   Gibson, Todd M ^c   Leisenring, Wendy ^g   Armstrong, Gregory T ^c   Robison, Leslie L ^c   Neglia, Joseph P ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ASTROCYTOMA; BREAST CANCER; CANADA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CHILDHOOD CANCER; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LIMIT OF QUANTITATION; LONGITUDINAL STUDY; MALE; MENINGIOMA; NON MELANOMA SKIN CANCER; RADIATION DOSE; RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; STANDARDIZATION; TERTIARY CARE CENTER; THYROID CANCER; TREND STUDY; ADOLESCENT; CHILD; CLINICAL TRIAL; MULTICENTER STUDY; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVOR; TIME FACTOR; UNITED STATES;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CANADA; CHILD; FEMALE; HUMANS; MALE; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVORS; TIME FACTORS; UNITED STATES;

EID: 85014655649     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.0693     Document Type: Review

References (37)

1. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100(19):1368-1379.
2. Hudson MM, Mertens AC, Yasui Y, et al; Childhood Cancer Survivor Study Investigators. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA. 2003;290 (12):1583-1592.
3. Kurt BA, Nolan VG, Ness KK, et al. Hospitalization rates among survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. Pediatr Blood Cancer. 2012; 59(1):126-132.
4. Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374(9):833-842.
5. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009;27 (14):2308-2318.
6. Bhatia S, Armenian SH, Armstrong GT, et al. Collaborative research in childhood cancer survivorship: the current landscape. J Clin Oncol. 2015;33(27):3055-3064.
7. Friedman DL, Whitton J, LeisenringW, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083-1095.
8. Garwicz S, Anderson H, Olsen JH, et al; Nordic Society for Pediatric Hematology and Oncology, Association of the Nordic Cancer Registries. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. Int J Cancer. 2000; 88(4):672-678.
9. Jenkinson HC, Hawkins MM, Stiller CA, Winter DL, Marsden HB, Stevens MC. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer. 2004;91(11):1905-1910.
10. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the Childhood Cancer Survivor Study. Radiat Res. 2010;174(6):840-850.
11. Borgmann A, Zinn C, Hartmann R, et al; ALL-REZ BFM Study Group. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer. 2008;44(2):257-268.
12. Kim SH, Shin KH, Seok SO, et al. Secondary malignant neoplasms after osteosarcoma: early onset and cumulative alkylating agent dose dependency. Ann Surg Oncol. 2015;22(3):859-865.
13. Pole JD, Gu LY, Kirsh V, Greenberg ML, Nathan PC. Subsequent malignant neoplasms in a population-based cohort of pediatric cancer patients: a focus on the first 5 years. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1585-1592.
14. Hudson MM, Neglia JP,WoodsWG, et al. Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer. 2012;58(3):334-343.
15. Green DM, Kun LE, Matthay KK, et al. Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pediatr Blood Cancer. 2013;60(7):1083-1094.
16. Leisenring WM, Mertens AC, Armstrong GT, et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2319-2327.
17. Fritz AG. International Classification of Diseases for Oncology: ICD-O. Geneva, Switzerland: World Health Organization; 2000.
18. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002;38 (4):229-239.
19. Green DM, Nolan VG, Goodman PJ, et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014;61(1):53-67.
20. Dong H, Robison LL, Leisenring WM, Martin LJ, Armstrong GT, Yasui Y. Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count. Am J Epidemiol. 2015;181(7):532-540.
21. Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol. 2016;17(9):1325-1334.
22. Surveillance, Epidemiology, and End Results Program (SEER), National Cancer Institute (NCI). SEER Cancer Statistics Review (CSR), 1975-2012. NCI website. https://seer.cancer.gov/archive/csr/1975-2012/.Accessed January 27, 2017.
23. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173-1182.
24. Hayes AF. Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach. New York, NY: Guilford Press; 2013.
25. MacKinnon DP, Fairchild AJ, Fritz MS. Mediation analysis. Annu Rev Psychol. 2007;58:593-614.
26. Armstrong GT, LiuW, LeisenringW, et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2011;29(22):3056-3064.
27. Inskip PD, Robison LL, Stovall M, et al. Radiation dose and breast cancer risk in the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(24):3901-3907.
28. Sigurdson AJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet. 2005;365 (9476):2014-2023.
29. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26): 2730-2741.
30. Green DM, Hyland A, Barcos MP, et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol. 2000;18(7):1492-1499.
31. Omer B, Kadan-Lottick NS, Roberts KB, et al. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br J Haematol. 2012;158(5):615-625.
32. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334(12):745-751.
33. Bhatia S, Yasui Y, Robison LL, et al; Late Effects Study Group. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21(23):4386-4394.
34. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015;373(26):2499-2511.
35. Reulen RC, Frobisher C, Winter DL, et al; British Childhood Cancer Survivor Study Steering Group. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA. 2011; 305(22):2311-2319.
36. Olsen JH, Möller T, Anderson H, et al. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst. 2009;101(11):806-813.
37. Turcotte LM, Whitton JA, Friedman DL, et al. Risk of subsequent neoplasms during the fifth and sixth decades of life in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2015;33(31): 3568-3575.